natgillin/translations-raw huggingface dataset:
If you do not inject your dose right away, small clumps of medicine may form in the pen and you may not get your full dose. 
Če odmerka ne injicirate takoj, lahko v peresniku nastanejo majhne grudice zdravila in tako ne dobite celotnega odmerka.
The suspension should be visually inspected prior to use. 
Pred uporabo je treba suspenzijo pregledati.
Throw away any Bydureon kit that has been frozen. 
Zavrzite vsak set zdravila Bydureon, ki je bil zamrznjen.
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that exhibits several antihyperglycaemic actions of glucagon-like peptide-1 (GLP-1). 
Eksenatid je agonist na receptorju za glukagonu podobnem peptidu-1 (GLP-1), ki kaže nekaj antihiperglikemičnih učinkov glukagonu podobnega peptida-1 (GLP-1).
The suspension should only be used if it is evenly mixed, white to off-white and cloudy, with no white medicine seen along the side, bottom or top of the pen window. 
Suspenzijo se sme uporabiti, le če je enakomerno premešana, bela do skoraj bela in motna ter ni belega zdravila videti nikjer ob strani, na dnu ali na vrhu okenca peresnika.
You should not see any clumps in the liquid. 
V tekočini ne smete videti nobenih grudic.
Wash your hands while the pen is warming up. 
Medtem ko se peresnik ogreva, si umijte roke.
• Talk with your doctor, pharmacist or diabetes nurse • Read the Package Leaflet carefully 
• Pogovorite se z zdravnikom ali medicinsko sestro v diabetološki ambulanti • Previdno preberite Navodilo za uporabo
For both prolonged-release exenatide formulations, the improvement in fasting plasma glucose concentrations was sustained through 52 weeks. 
Za obe formulaciji eksenatida v obliki s podaljšanim sproščanje je izboljšanje v koncentraciji glukoze v plazmi na tešče trajalo vseh 52 tednov.
Bydureon is injected into your skin (subcutaneously). 
Zdravilo Bydureon se injicira v kožo (subkutano).
If you stop using Bydureon 
Če ste prenehali uporabljati zdravilo Bydureon
• Push the pen against your skin. 
• pritisnite peresnik na kožo.
The incidence of hypoglycaemia was increased when prolonged-release exenatide was used in combination with a sulphonylurea (24.0% versus 5.4%) (see section 4.4). 
Incidenca hipoglikemije je bila zvišana ob uporabi eksenatida v obliki s podaljšanim sproščanjem v kombinaciji s sulfonilsečnino (24,0 % proti 5,4 %) (glejte poglavje 4.4).
Green shield pops up 
Zeleni ščitnik izskoči navzgor
A pharmacodynamic study with exenatide demonstrated in patients with type 2 diabetes (n = 13) a restoration of first phase insulin secretion and improved second phase insulin secretion in response to an intravenous bolus of glucose. 
Farmakodinamične študije eksenatida so pokazale, da se pri bolnikih z diabetesom tipa 2 (n = 13) popravi prva faza izločanja insulina in izboljša druga faza izločanja insulina v odzivu na bolus injekcije glukoze.
What Bydureon is and what it is used for What you need to know before you use Bydureon How to use Bydureon 
Kaj je zdravilo Bydureon in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Bydureon Kako uporabljati zdravilo Bydureon Možni neželeni učinki
After removing the needle, look for the orange rod in the window as a way to tell that the dose has been given. 
Potem ko iglo odmaknete, preverite, ali je v okencu oranžna paličica; to vam pove, da je bil odmerek dan.
While holding the pen upright with the needle cover uppermost, twist the knob anticlockwise until the orange label disappears and the injection button is released. 
Medtem ko držite peresnik pokonci s pokrovčkom igle, obrnjenim navzgor, obračajte gumb v nasprotni smeri urinega kazalca, dokler oranžna nalepka ne izgine in se sprosti gumb za injiciranje.
BCise is the name of the pre-filled pen device used to inject your Bydureon medicine. 
BCise se imenuje napolnjen injekcijski peresnik, s katerim si injicirate vaše zdravilo Bydureon.
Uneven mix White medicine on bottom, top, or sides 
Neenakomerna mešanica Belo zdravilo na dnu, na vrhu ali ob straneh
What Bydureon looks like and contents of the pack 
Izgled zdravila Bydureon in vsebina pakiranja
The clinical experience in patients with moderate renal impairment is limited and the use of prolonged-release exenatide is not recommended. 
Kliničnih izkušenj pri bolnikih z zmerno okvaro ledvic je malo, zato uporaba eksenatida v obliki s podaljšanim sproščanjem ni priporočljiva.
The effect on beta-cell function was sustained through 52 weeks. 
Učinek na beta celice je trajal vseh 52 tednov.
In addition, injection site reactions (pruritus, nodules, erythema), hypoglycaemia (with a sulphonylurea), and headache occurred. 
Pojavile so se tudi reakcije na mestu injiciranja (pruritus, noduli, eritrem), hipoglikemija (s sulfonilsečninami) in glavobol.
To be sure you get your full dose, press the injection button with your thumb until you hear a click. 
Da boste prepričani, da ste dobili celoten odmerek, s palcem pritisnite gumb za injiciranje, dokler ne zaslišite klika.
Sodium content: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium-free”. 
Vsebnost natrija: Zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni “brez natrija”.
IMPORTANT Once the medicine is mixed well, you must inject the dose immediately. 
POMEMBNO: Ko je zdravilo dobro premešano, morate takoj injicirati odmerek.
Prolonged-release exenatide must not be administered by intravenous or intramuscular injection. 
Eksenatida v obliki s podaljšanim sproščanjem ne smemo dati intravensko ali intramuskularno.
Common Uncommon Rare Very rare Not known 
Pogostnost pojavljanja zelo pogosti pogosti občasni redki zelo redki neznana pogostnost
Green label 
Zelena nalepka
Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea and of insulin, particularly when prolonged-release exenatide therapy is started and insulin is reduced. 
Bolnikov samonadzor glukoze v krvi pa je potreben za prilagajanje odmerka sulfonilsečnine in insulina, zlasti ob začetku zdravljenja z eksenatidom v obliki s podaljšanim sproščanjem in zmanjšanju odmerka insulina.
Each carton contains 4 single-dose kits: 
Vsaka škatla vsebuje 4 enoodmerne sete:
Caution should be exercised in patients with a history of pancreatitis. 
Pri bolnikih, ki so v preteklosti že imeli pankreatitis, je potrebna previdnost.
• Keep the pen, and all medicines, out of the reach of children. 
• Peresnik in vsa zdravila shranjujte nedosegljiva otrokom.
• STOP taking this medicine and contact your doctor immediately if you experience severe and persistent stomach pain, with or without vomiting, because you could have an inflamed pancreas (pancreatitis). 
• Če občutite hude in dolgotrajne bolečine v trebuhu, z bruhanjem ali brez njega, PRENEHAJTE z jemanjem tega zdravila in takoj obvestite zdravnika, saj imate lahko vnetje trebušne slinavke (pankreatitis).
One study was of 24 weeks in duration (n = 252) and the other of 30 weeks (n = 295) followed by an open-labelled extension where all patients were treated with prolonged-release exenatide 2 mg once weekly for a further 7 years (n = 258). 
Ena študija je trajala 24 tednov (n = 252), druga pa 30 tednov (n = 295), čemur je sledilo odprto podaljšanje, kjer so bili vsi bolniki zdravljeni z eksenatidom v obliki s podaljšanim sproščanjem 2 mg enkrat tedensko nadaljnjih 7 let (n = 258).
− medicines used to thin the blood (anticoagulants), e.g. Warfarin, as you will require additional monitoring of changes in INR (measurement of blood thinning) during initiation of therapy with this medicine. 
- zdravila za redčenje krvi (antikoagulanti), na primer varfarin, ker boste med uvajanjem tega zdravila potrebovali dodatno spremljanje sprememb INR (merilo za gostoto krvi).
Put the vial down. 
Odložite vialo.
Most episodes of nausea were mild to moderate. 
Večina epizod navzee je bila blaga do zmerna.
This draws the medicine from the vial into the syringe. 
To omogoči, da zdravilo preide iz viale v injekcijsko brizgo.
Remove the needle from your skin and replace it with the spare needle from the carton. 
Potegnite iglo iz kože in jo zamenjajte z rezervno iglo, ki je v škatli.
The liquid in the syringe should be clear and free of particles. 
Tekočina v injekcijski brizgi mora biti bistra in brez delcev.
Due to the long washout period of prolonged-release exenatide, women of childbearing potential should use contraception during treatment with prolonged-release exenatide. 
Zaradi dolgega odstranjevanja eksenatida v obliki s podaljšanim sproščanjem iz telesa morajo ženske v rodni dobi med zdravljenjem z eksenatidom v obliki s podaljšanim sproščanjem uporabljati kontracepcijo.
Gastrointestinal disorders Intestinal obstruction Acute pancreatitis (see section 4.4) 
Bolezni prebavil intestinalna obstrukcija akutni pankreatitis (glejte poglavje 4.4).
These injection site reactions were generally mild and usually did not lead to discontinuation of study medication. 
Te reakcije na mestu injiciranja so bile večinoma blage in niso vodile do prekinitve zdravljenja z raziskovanim zdravilom.
Orange Label 
Oranžna nalepka
Pick up the vial connector package and peel off the paper cover. 
Vzemite povezovalec viale in odstranite papirno zaščito.
B. Shake the pen hard, in an up-and-down motion, until the medicine is mixed evenly and you do not see any white medicine along the sides, bottom or top. 
B. Peresnik močno pretresite z gibi navzgor-navzdol, dokler ni zdravilo enakomerno premešano in ne vidite nič belega zdravila ob straneh, na dnu ali na vrhu.
With one hand, hold the syringe near the black dashed Dose Line. 
Z eno roko držite injekcijsko brizgo blizu črne odmerne črte.
-Placebo favored-> 
-V korist placeba->
#nominal p-value <0.05, 
#nominalni p < 0,05,
Now, pick up the vial with the orange connector attached. 
Sedaj vzemite vialo s pritrjenim oranžnim povezovalcem.
The “Instructions for the User”, provided in the carton, must be followed carefully. 
Natančno je treba upoštevati “Navodila za uporabnika”, ki so priložena v škatli.
Insulin glargine was dosed to a target glucose concentration of 4.0 to 5.5 mmol/l (72 to 100 mg/dl). 
Insulin glargin je bil odmerjen do ciljne koncentracije glukoze med 4,0 in 5,5 mmol/l (72 do 100 mg/dl).
I'm ready to take the injection. 
Pripravljen/a sem na injekcijo.
In clinical studies of prolonged-release exenatide, acute pancreatitis occurred in 0.3% of patients. 
V kliničnih študijah eksenatida v obliki s podaljšanim sproščanjem se je akutni pankreatitis pojavil pri 0,3 % bolnikov.
Event Rate HR (95% CI)1 
Delež dogodkov ROg (95 % IZ)1
The orange connector will keep it attached to the syringe. 
Oranžni povezovalec bo poskrbel, da bo ostala nataknjena na injekcijsko brizgo.
In your other hand, hold the vial. 
Z drugo roko držite vialo.
Cardiovascular evaluation 
Srčno-žilno ovrednotenje
NAME AND ADDRESS OF THE MARKETINGAUTHORISATION HOLDER 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
When prolonged-release exenatide was added to basal insulin, no initial dose adjustment of insulin was required. 
Če je bil eksenatid v obliki s podaljšanim sproščanjem dodan bazalnemu insulinu, začetnega odmerka insulina ni bilo treba prilagoditi.
With your other hand, hold the needle cover. 
Z drugo roko držite pokrovček igle.
Press the injection button with your thumb until you hear a click. 
S palcem pritisnite gumb za injiciranje, dokler ne zaslišite klika.
Do not use this medicine after the expiry date, which is stated on the label and the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
The powder (2 mg) in one chamber, is white to off-white and the solvent (0.65 ml) in the other chamber, is a clear, colourless to pale yellow to pale brown solution. 
Prašek (2 mg) v enem prekatu je bel do belkast in vehikel (0,65 ml) v drugem prekatu je bistra, brezbarvna do bledo rumena oziroma do bledo rjava raztopina.
Prolonged-release exenatide was associated with a significantly lower incidence of episodes of hypoglycaemia than basal insulin in patients also receiving metformin therapy (3% versus 19%) and in patients also receiving metformin plus sulphonylurea therapy (20% versus 42%). 
V primerjavi z bazalnim insulinom je bil eksenatid v obliki s podaljšanim sproščanjem povezan z znatno nižjo incidenco epizod hipoglikemije pri bolnikih, ki so sočasno prejemali metformin (3 % proti 19 %) in pri bolnikih, ki so sočasno prejemali metformin in sulfonilsečnino (20 % proti 42 %).
Posology The recommended dose is 2 mg exenatide once weekly. 
Odmerjanje Priporočen odmerek je 2 mg eksenatida enkrat tedensko.
Important: After the medicine is fully mixed, you must complete the preparation steps right away, and inject to get the full dose. 
Pomembno: Ko je zdravilo povsem premešano, morate takoj opraviti korake za pripravo in zdravilo injicirati, da boste dobili celoten odmerek.
Remember, before preparing your dose, leave the pen out of the refrigerator for at least 15 minutes. 
Ne pozabite: pred pripravo odmerka morate peresnik vsaj 15 minut pustiti zunaj hladilnika.
Exenatide improves glycaemic control through the sustained effects of lowering both postprandial and fasting glucose concentrations in patients with type 2 diabetes. 
Eksenatid izboljša glikemični nadzor s takojšnjimi in trajnimi učinki zniževanja tako postprandialne koncentracije glukoze kot koncentracije glukoze na tešče pri bolnikih z diabetesom tipa 2.
Once you mix the medicine, you must inject it immediately. 
Ko enkrat zmešate zdravilo, ga morate nemudoma uporabiti.
The LS means change in mean daily insulin dose was 1.6 units for the prolonged-release exenatide group and 3.5 units for the placebo group. 
Povprečna sprememba po metodi LS povprečnega dnevnega odmerka insulina je bila 1,6 enote v skupini z eksenatidom v obliki s podaljšanim sproščanjem in 3,5 enote v skupini s placebom.
Overall the percentage of antibody positive patients was consistent across clinical studies. 
Celostno je bil odstotek bolnikov s pozitivnimi protitelesi v kliničnih študijah podoben.
I'm ready to inject my dose. 
Pripravljen sem za injiciranje odmerka.
When used with insulin, prolonged-release exenatide and insulin must be administered as two separate injections. 
Če se eksenatid v obliki s podaljšanim sproščanjem uporablja skupaj z insulinom, je potrebno zdravili dati v dveh ločenih injekcijah.
When prolonged-release exenatide is added to existing metformin and/or thiazolidinedione therapy, the current dose of metformin and/or thiazolidinedione can be continued. 
Kadar dodamo eksenatid v obliki s podaljšanim sproščanjem k obstoječemu zdravljenju z metforminom in/ali tiazolidindionom, lahko nadaljujemo s predpisanim odmerkom metformina in/ali tiazolidindiona.
Exenatide is cleared primarily by the kidney, therefore hepatic dysfunction is not expected to affect blood concentrations of exenatide. 
Eksenatid se izloča zlasti preko ledvic, zato ni pričakovati, da bi okvara jeter vplivala na koncentracije eksenatida v krvi.
The European Medicines Agency has deferred the obligation to submit the results of studies with prolonged-release exenatide in one or more subsets of the paediatric population in type 2 diabetes mellitus (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odložila zahtevo za predložitev rezultatov študij z eksenatidom v obliki s podaljšanim sproščanjem za eno ali več podskupin pediatrične populacije z diabetesom mellitusom tipa 2 (za informacije o pediatrični uporabi glejte poglavje 4.2).
During the controlled period of the clinical studies, injection site reactions were observed more frequently in patients treated with Bydureon BCise versus comparator-treated patients (24% versus 4% with immediate-release exenatide). 
Med kontroliranim obdobjem kliničnih študij so ugotovili, da so bile reakcije na mestu injiciranja pri bolnikih, ki so se zdravili z zdravilom Bydureon BCise, bolj pogoste kot pri zdravljenju s primerjalnimi zdravili (24 % v primerjavi s 4 % med uporabo eksenatida v obliki s takojšnjim sproščanjem).
When used in combination with a sulphonylurea, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines. 
Kadar ga uporabljamo v kombinaciji s sulfonilsečnino, moramo bolnikom svetovati o previdnostnih ukrepih, da bi se med vožnjo in upravljanjem strojev izognili hipoglikemiji.
How do I know I gave myself the full dose of medicine? 
Kako naj vem, ali sem si dal(a) celotni odmerek zdravila?
These injection site reactions were generally mild and usually did not lead to withdrawal from studies. 
Te reakcije na mestu injiciranja so bile večinoma blage in niso vodile do prekinitve študije.
If a dose is missed and the next regularly scheduled dose is due 1 or 2 days later, the patient should not administer the missed dose, but instead resume prolonged-release exenatide on the next regularly scheduled dosing day. 
V primeru, da bolnik izpusti odmerek, naslednji redni odmerek pa je na vrsti 1 ali 2 dneva pozneje, naj ne uporabi izpuščenega odmerka, temveč naj namesto tega nadaljuje z uporabo eksenatida v obliki s podaljšanim sproščanjem na naslednji običajni dan uporabe zdravila po urniku.
Exenatide suppresses glucagon secretion which is known to be inappropriately elevated in patients with type 2 diabetes. 
Eksenatid zavre izločanje glukagona, ki je pri bolnikih z diabetesom tipa 2 neustrezno povečano.
For instructions on the suspension of the medicinal product before administration, see section 6.6 and the “Instructions for the User”. 
Za navodila o pripravi suspenzije pred dajanjem glejte poglavje 6.6 in “Navodila za uporabnika”.
Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control. 
Zdravilo Bydureon je indicirano pri odraslih bolnikih, starih 18 let ali več, ki imajo sladkorno bolezen tipa 2, za izboljšanje urejenosti glikemije v kombinaciji z drugimi zdravili za zniževanje glukoze vključno z bazalnim insulinom, če trenutno uporabljana zdravila (skupaj s prehrano in telesno dejavnostjo) ne zagotovijo ustrezne urejenosti glikemije.
This will let the pen warm up to room temperature. 
Tako se bo peresnik ogrel na sobno temperaturo.
In a 30-week study, approximately 3% (n = 4/148) of prolonged-release exenatide treated patients experienced at least one time period of rapid weight loss (recorded body weight loss between two consecutive study visits of greater than 1.5 kg/week). 
V 30-tedenski študiji je približno 3 % (n = 4/148) bolnikov, ki so se zdravili z eksenatidom v obliki s podaljšanim sproščanjem, v vsaj enem časovnem obdobju izkusilo hitro izgubo telesne mase (izmerjena izguba telesne mase med dvema zaporednima obiskoma večja od 1,5 kg/teden).
If a dose is missed, it should be administered as soon as practical, provided the next regularly scheduled dose is due in 3 days or more. 
V primeru zamujenega odmerka je tega potrebno dati čim prej, ko je to mogoče, a pod pogojem, da je do uporabe naslednjega rednega odmerka 3 dni ali več.
Review the Instructions for the User Step 3 to confirm the order of operations, also confirm that the knob is fully in the unlocked position, then contact the local representative of the Marketing Authorisation Holder (see section 6 of the Package Leaflet for a list of contacts by country). 
Ponovno preglejte 3. korak v navodilih za uporabnika, da boste preverili zaporedje operacij; preverite tudi, da je gumb povsem v položaju "odklenjeno", nato se obrnite na lokalnega predstavnika imetnika dovoljenja za promet z zdravilom (glejte poglavje 6 v navodilu za uporabo za seznam kontaktnih podatkov po državah).
The incidence of withdrawal due to adverse events during the 30-week controlled study was 6% for prolonged-release exenatide treated patients, 5% for immediate-release exenatide treated patients. 
Incidenca prekinitve zdravljenja zaradi neželenih učinkov v 30-tedenski kontrolirani študiji je bila pri bolnikih, zdravljenih z eksenatidom v obliki s podaljšanim sproščanjem, 6 % in pri bolnikih, zdravljenih z eksenatidom v obliki s takojšnim sproščanjem, 5 %.
In the 4 comparator-controlled studies, the proportion of patients who had both a reduction in weight and HbA1c ranged from 70 to 79% (the proportion of patients who had a reduction of HbA1c ranged from 88 to 96%). 
V 4 s primerjalnimi zdravili kontroliranih študijah je bil delež bolnikov, pri katerih je prišlo do zmanjšanja telesne mase in HbA1c, med 70 in 79 % (delež bolnikov, pri katerih je prišlo do zmanjšanja HbA1c je bil 88 do 96 %).
Mix the suspension by shaking hard for at least 15 seconds. 
Suspenzijo premešajte tako, da peresnik vsaj 15 sekund močno stresate.
• Tap the prefilled pen firmly until a uniformly cloudy suspension with no clumps is obtained. 
• Odločno potrkavajte s peresnikom, dokler ne dobite enakomerno motne suspenzije brez grudic.
Pens stored vertically (with the needle up or down) are more difficult to mix. 
Če je peresnik shranjen v pokončnem položaju (z iglo obrnjeno navzgor ali navzdol), je zdravilo težje premešati.
This medicine is used in combination with the following diabetes medicines: metformin, sulphonylureas, thiazolidinediones, SGLT2 inhibitors and/or a long-acting insulin. 
To zdravilo uporabljamo v kombinaciji z naslednjimi zdravili za sladkorno bolezen: metformin, sulfonilsečnine, tiazolidindioni, zaviralci SGLT2 in/ali dolgodelujoči insulin.
How do I know if the medicine is fully mixed? 
Kako naj vem, ali je zdravilo popolnoma premešano?
Rate based on prolonged-release exenatide spontaneous reports data (unknown denominator). 
Pogostnost na podlagi podatkov spontanih poročil o eksenatidu v obliki s podaljšanim sproščanjem (neznan imenovalec).
Vehicle Medium chain triglycerides 
Vehikel srednjeverižni trigliceridi
D. Choose your injection site. 
D. Izberite mesto za injiciranje.
Hidden Needle 
Prekrita igla
Approximately 10 weeks after discontinuation of prolonged-release exenatide therapy, mean plasma exenatide concentrations fell below minimal detectable concentrations. 
Približno 10 tednov po prenehanju zdravljenja z eksenatidom v obliki s podaljšanim sproščanjem srednja vrednost plazemske koncentracije eksenatida pade pod minimalno zaznavno koncentracijo.
Table 1: Adverse reactions of Bydureon BCise identified from clinical studies 
Preglednica 1: Neželeni učinki zdravila Bydureon BCise, ugotovljeni v kliničnih študijah
Mixing the medicine and filling the syringe 
Mešanje zdravila in polnjenje injekcijske brizge
You will hear a “click” when the injection begins. 
Ko se bo injiciranje začelo, boste slišali "klik".
What should I do if I cannot push the injection button all the way in when trying to inject my dose? 
Kaj naj naredim, če pri injiciranju odmerka gumba za injiciranje ne morem potisniti do konca noter?
If you don't see clumps you are ready to inject. 
Če ne vidite grudic, je zdravilo pripravljeno za injiciranje.
These include: cavity containing pus (abscess) and swollen, or red area of skin that feels hot and tender (cellulitis). 
Med takšnimi so: z gnojem napolnjena votlina (absces) in oteklost ali pordelost kože, ki je vroča in boleča (flegmona).
The European Medicines Agency has deferred the obligation to submit the results of studies with prolonged-release exenatide formulations in one or more subsets of the paediatric population in type 2 diabetes mellitus (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odložila zahtevo za predložitev rezultatov študij z eksenatidom v oblikah s podaljšanim sproščanjem za eno ali več podskupin pediatrične populacije z diabetesom mellitusom tipa 2 (za informacije o pediatrični uporabi glejte poglavje 4.2).
What should I do if I see air bubbles in the syringe? 
Kaj naj naredim, če v injekcijski brizgi vidim zračne mehurčke?